Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Drug Profile

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Alternative Names: DART candidates - MacroGenics/Pfizer; DART Oncology; EphA2xCD3 DART; IL1Ra2xCD3 DART; MGD 013; MGD-15; ROR1xCD3 DART

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator MacroGenics
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action CD223 antigen inhibitors; CD3 antigen modulators; Interleukin 13 receptor modulators; PDCD 1 protein inhibitors; Receptor tyrosine kinase-like orphan receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Aug 2016 Preclinical development is ongoing in USA
  • 03 Aug 2016 MacroGenics announces intention to submit IND to US FDA for MGD 013 in 2017
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top